@article{98c55b87f5e240ca862cf27c600c8291,
title = "Classical and noncanonical functions of miRNAs in cancers",
abstract = "Alterations in microRNAs (miRNAs) expression are causative in the initiation and progression of human cancers. The molecular events responsible for the widespread differential expression of miRNAs in malignancy are exemplified by their location in cancer-associated genomic regions, epigenetic mechanisms, transcriptional dysregulation, chemical modifications and editing, and alterations in miRNA biogenesis proteins. The classical miRNA function is synonymous with post-transcriptional repression of target protein genes. However, several studies have reported miRNAs functioning outside this paradigm and some of these novel modes of regulation of gene expression have been implicated in cancers. Here, we summarize key aspects of miRNA involvement in cancer, with a special focus on these lesser-studied mechanisms of action.",
keywords = "cancer, germline and somatic mutations, miRNA, miRNA mimicry, non-canonical functions, pri- and pre-miRNA regulation",
author = "Dragomir, {Mihnea P.} and Erik Knutsen and Calin, {George A.}",
note = "Funding Information: M.P.D. is a participant in the BIH-Charit? Junior Clinical Scientist Program funded by the Charit? ? Universit?tsmedizin Berlin and the Berlin Institute of Health. E.K. is funded by The Northern Norway Regional Health Authority (HNF1585-21). G.A.C. is the Felix L. Haas Endowed Professor in Basic Science. Work in G.A.C's laboratory is supported by a National Institutes of Health (NIH/NCATS) grant UH3TR00943-01 through the NIH Common Fund, Office of Strategic Coordination (OSC), the NCI grants 1R01 CA182905-01 and 1R01CA222007-01A1, an NIGMS 1R01GM122775-01 grant, a Team Department of Defense (CA160445P1) grant, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a CLL Global Research Foundation 2019 grant, a CLL Global Research Foundation 2020 grant, and the Estate of C.G. Johnson, Jr., G.A.C. is the scientific founder of Ithax Pharmaceuticals. The other authors declare no conflict of interest. Funding Information: M.P.D. is a participant in the BIH-Charit{\'e} Junior Clinical Scientist Program funded by the Charit{\'e} – Universit{\"a}tsmedizin Berlin and the Berlin Institute of Health . E.K. is funded by The Northern Norway Regional Health Authority ( HNF1585-21 ). G.A.C. is the Felix L. Haas Endowed Professor in Basic Science . Work in G.A.C{\textquoteright}s laboratory is supported by a National Institutes of Health (NIH/NCATS) grant UH3TR00943-01 through the NIH Common Fund , Office of Strategic Coordination (OSC), the NCI grants 1R01 CA182905-01 and 1R01CA222007-01A1 , an NIGMS 1R01GM122775-01 grant, a Team Department of Defense ( CA160445P1 ) grant, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a CLL Global Research Foundation 2019 grant, a CLL Global Research Foundation 2020 grant, and the Estate of C.G. Johnson, Jr. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2022",
month = apr,
doi = "10.1016/j.tig.2021.10.002",
language = "English (US)",
volume = "38",
pages = "379--394",
journal = "Trends in Genetics",
issn = "0168-9525",
publisher = "Elsevier Limited",
number = "4",
}